California, USA-based Lyell Immunopharma has entered into a definitive agreement to acquire privately-held US CAR-T company ...

The US Food and Drug Administration (FDA) approved Iterum Therapeutics’ (Nasdaq: ITRM) Orlynvah (sulopenem etzadroxil and ...

Viking Therapeutics plans to advance its obesity drug VK2735 to Phase III trials by late 2024, following Phase II results ...

GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. The UK ...

Biostar Pharmaceuticals plans to raise funds through an IPO on the Hong Kong Stock Exchange, offering 14.6 million shares at ...

Advisory Committee on Immunization Practices (ACIP) voted to update the adult age-based pneumococcal vaccination guidelines ...

Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface ...

Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart ...

Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with ...

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant ...

New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with ...

Intellia Therapeutics reported positive Phase II results for its CRISPR therapy NTLA-2002, showing an 81% reduction in ...